Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 6,526 other HR bills in the 114th — cohort avg 56d
Family Cord Blood Banking Act This bill amends the Internal Revenue Code to treat the cost of private umbilical cord blood or tissue, or placental blood or tissue, banking services as a medical care expense for purposes of the tax deduction for medical expenses.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2016 · fourth_quarter · Health Issues
Policy and implementation issues relating to Public Law No. 111-148, the Patient Protection and Affordable Care Act. Policy and implementation issues relating to Public Law No. 112-144, the Food and Drug Administration Safety and Innovation Act, specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the Food and Drug Administration Amendments Act, specifically FDA's Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 34, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. S. 1566, the Cancer Drug Coverage Parity Act. H.R. 3982, the Family Cord Blood Banking Act.
Referred to the House Committee on Ways and Means.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Policy and implementation issues relating to Public Law No. 111-148, the Patient Protection and Affordable Care Act. Policy and implementation issues relating to Public Law No. 112-144, the Food and Drug Administration Safety and Innovation Act, specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the Food and Drug Administration Amendments Act, specifically FDA's Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. S. 1566, the Cancer Drug Coverage Parity Act. H.R. 3982, the Family Cord Blood Banking Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Taxation/Internal Revenue Code
H.R. 3982, the "Family Cord Blood Banking Act." Policy issues relating to corporate tax reform.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the "21st Century Cures Act. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 2841, the "Fair Access for Safe and Timely Generics Act." H.R. 1600, the "Patients' Access to Treatments Act." H.R. 2739, the "Cancer Drug Coverage Parity Act." S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the "Family Cord Blood Banking Act."
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
Policy and implementation issues relating to Public Law No. 111-148, the Patient Protection and Affordable Care Act. Policy and implementation issues relating to Public Law No. 112-144, the Food and Drug Administration Safety and Innovation Act, specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the Food and Drug Administration Amendments Act, specifically FDA's Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. S. 1566, the Cancer Drug Coverage Parity Act. H.R. 3982, the Family Cord Blood Banking Act.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Taxation/Internal Revenue Code
H.R. 3982, the "Family Cord Blood Banking Act." Policy issues relating to corporate tax reform.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the Family Cord Blood Banking Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Taxation/Internal Revenue Code
H.R. 3982, the "Family Cord Blood Banking Act." Policy issues relating to corporate tax reform.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases. Policy issues relating to patient cost-sharing for specialty medicines. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. H.R. 3982, the Family Cord Blood Banking Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| NY |
| Charles W. Boustany Jr. | Republican | LA |
| Dan Benishek | Republican | MI |
| Donald M. Payne, Jr. | Democratic | NJ |
| J. Randy Forbes | Republican | VA |
| Joe Wilson | Republican | SC |
| John Lewis | Democratic | GA |
| Kenny Marchant | Republican | TX |
| Leonard Lance | Republican | NJ |
| Matt Cartwright | Democratic | PA |
| Ron Kind | Democratic | WI |
| Thomas MacArthur | Republican | NJ |